<DOC>
	<DOCNO>NCT01844284</DOCNO>
	<brief_summary>Prospective , Randomized ( 2:1 ) , active control , single-blind , non-inferiority , multicenter , Japanese Clinical Trial evaluate safety effectiveness Absorb™ BVS ( AVJ-301 ) treatment subject ischemic heart disease cause de novo native coronary artery lesion Japanese population compare approve metallic drug elute stent .</brief_summary>
	<brief_title>AVJ-301 Clinical Trial : A Clinical Evaluation AVJ-301 ( Absorb™ BVS ) Japanese Population</brief_title>
	<detailed_description>Absorb™ BVS currently development Abbott Vascular . Not available sale US Japan .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Subject must least 20 year age . 2 . Subject legally authorize representative must provide write Informed Consent prior study related procedure , per site requirement . 3 . Subject must evidence myocardial ischemia ( e.g. , stable unstable angina , silent ischemia ) suitable elective percutaneous coronary intervention ( PCI ) . 4 . Subject must acceptable candidate coronary artery bypass graft ( CABG ) surgery . 5 . Subject must able take dual antiplatelet therapy 1 year follow index procedure anticoagulant prior/during index procedure . Therefore subject know allergic reaction , hypersensitivity contraindication aspirin , clopidogrel , ticlopidine heparin . 6 . Female subject childbearing potential must pregnant* index procedure plan pregnancy 1 year follow index procedure . * Except nonpregnancy apparent , negative pregnancy result within 7 day prior index procedure require . 7 . Female subject breastfeeding time screen visit breastfeed 1 year follow index procedure . 8 . Subject agree participate investigational invasive clinical study period 13 month follow index procedure 1 . Elective surgery plan within 1 year procedure require general anesthesia discontinue either aspirin Thienopyridine . 2 . Subject know hypersensitivity contraindication device material degredants ( everolimus , poly ( Llactide ) , poly ( DLlactide ) , lactide , lactic acid ) cobalt , chromium , nickel , platinum , tungsten , acrylic fluoro polymer adequately premedicated . 3 . Subject know contrast sensitivity adequately premedicated . 4 . Subject acute myocardial infarction ( AMI ) within 72 hour index procedure The subject currently experience clinical symptom consistent new onset AMI , nitrateunresponsive prolong chest pain ischemic ECG change CK CKMB return within normal limit time index procedure . 5 . Subject unstable cardiac arrhythmia likely become hemodynamically unstable due arrhythmia . 6 . Subject know leave ventricular ejection fraction ( LVEF ) &lt; 30 % ( LVEF may obtain time index procedure value unknown investigator believe necessary ) . 7 . The target vessel treat PCI within 12 month . 8 . Prior PCI within nontarget vessel acceptable perform anytime &gt; 30 day index procedure 24 hour 30 day index procedure successful uncomplicated . 9 . Subject require future stag PCI either target non target vessel . 10 . Subject malignancy remission . 11 . Subject receive immunosuppressant therapy know immunosuppressive autoimmune disease ( e.g. , human immunodeficiency virus , systemic lupus erythematosus , etc. , ) . Note : corticosteroid include immunosuppressant therapy , diabetes mellitus regard autoimmune disease . 12 . Subject receive solid organ transplant wait list solid organ transplant . 13 . Subject previously receive schedule receive radiotherapy coronary artery ( brachytherapy ) , chest/mediastinum . 14 . Subject receive require chronic anticoagulation therapy ( e.g. , coumadin agent reason ) . 15 . Subject platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 . 16 . Subject document suspected cirrhosis ChildPugh ≥ Class B . 17 . Subject know renal insufficiency ; Dialysis time screen . An estimated GFR &lt; 30 ml/min/1.73m2 18 . Subject high risk bleeding , difficult appropriate treatment ; Has history bleed diathesis coagulopathy Has significant gastrointestinal significant urinary bleed within past six month Has prior intracranial bleed Has prior intracranial bleed ( include severe permanent neurologic deficit seem cause previous intracranial bleeding ) Has know intracranial pathology may cause intracranial bleed per investigator assessment ( e.g . untreated aneurysm &gt; 5 mm , arteriovenous malformation ) Subject refuse blood transfusion 19 . Subject cerebrovascular accident transient ischemic neurological attack ( TIA ) within past six month , 20 . Subject extensive peripheral vascular disease precludes safe 6 French sheath insertion . 21 . Subject life expectancy &lt; 3 year . 22 . Subject opinion Investigator designee , unable comply requirement study protocol unsuitable study reason . 23 . Subject currently participate another clinical trial yet complete primary endpoint . 24 . Subject whose willingness volunteer clinical investigation could unduly influenced expectation , whether justify , benefit associate participation retaliatory response senior member hierarchy case refusal participate ( e.g . subordinate hospital staff sponsor staff ) subject unable read write .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Absorb™ BVS</keyword>
	<keyword>Angioplasty</keyword>
	<keyword>Bioabsorbable</keyword>
	<keyword>Bioreabsorbable</keyword>
	<keyword>BVS</keyword>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Coronary Artery Endothelial Responsiveness</keyword>
	<keyword>Coronary artery restenosis</keyword>
	<keyword>Coronary artery stenosis</keyword>
	<keyword>Coronary scaffold</keyword>
	<keyword>Coronary Stent</keyword>
	<keyword>Drug elute stent</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Myocardial ischemia</keyword>
	<keyword>Stent thrombosis</keyword>
	<keyword>Stents</keyword>
</DOC>